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Objectives: Drug safety surveillance using observational data requires valid adverse event, or health out-
come of interest (HOI) measurement. The objectives of this study were to develop a method to review
HOI deﬁnitions in claims databases using (1) web-based digital tools to present de-identiﬁed patient
data, (2) a systematic expert panel review process, and (3) a data collection process enabling analysis
of concepts-of-interest that inﬂuence panelists’ determination of HOI.
Methods: De-identiﬁed patient data were presented via an interactive web-based dashboard to enable
case review and determine if speciﬁc HOIs were present or absent. Criteria for determining HOIs and their
severity were provided to each panelist. Using a modiﬁed Delphi method, six panelist pairs indepen-
dently reviewed approximately 200 cases across each of three HOIs (acute liver injury, acute kidney
injury, and acute myocardial infarction) such that panelist pairs independently reviewed the same cases.
Panelists completed an assessment within the dashboard for each case that included their assessment of
the presence or absence of the HOI, HOI severity (if present), and data contributing to their decision. Dis-
crepancies within panelist pairs were resolved during a consensus process.
Results: Dashboard development was iterative, focusing on data presentation and recording panelists’
assessments. Panelists reported quickly learning how to use the dashboard. The assessment module
was used consistently. The dashboard was reliable, enabling an efﬁcient review process for panelists.
Modiﬁcations were made to the dashboard and review process when necessary to facilitate case review.
Our methods should be applied to other health outcomes of interest to further reﬁne the dashboard and
case review process.
Conclusion: The expert review process was effective and was supported by the web-based dashboard.
Our methods for case review and classiﬁcation can be applied to future methods for case identiﬁcation
in observational data sources.
 2013 Elsevier Inc. All rights reserved.1. Introduction
Adverse drug events (ADEs) continue to be a common problem
leading to signiﬁcant morbidity, mortality, and ﬁnancial costs
[1–7]. Serious limitations exist for two frequently used ADE
detection methods: clinical trials and post-marketing surveillance.
Clinical trials use narrowly deﬁned populations that, while rele-
vant to determining medication efﬁcacy, are usually too small to
identify ADEs to a meaningful extent. Post-marketing surveillance
mechanisms rely on spontaneous ADE reporting by clinical
researchers, health care professionals, and the public. Both meth-
ods provide limited value in identifying ADEs. Accordingly, theInstitute of Medicine (IOM) called for systematic use of automated
health care databases from a variety of settings to actively monitor
drug safety and efﬁcacy [8]. Congress subsequently mandated that
the FDA collaborate with a variety of groups to implement the
IOM’s recommendation [9].
The FDA Sentinel Initiative was borne out of Congress’ mandate,
and is focused on monitoring medical products throughout their
entire life cycle by using data from large, disparate electronic data
sources [10]. To this end, researchers are exploring approaches and
methods for the use of large observational data sources for active
safety surveillance, including the Mini-Sentinel project [11] and
the Observational Medical Outcomes Partnership (OMOP) [12].
These initiatives are founded on the belief that active surveillance
can be performed using administrative claims and electronic
health record (EHR) data. These observational data sources offer
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sources covering a large number of subjects, (2) the data are col-
lected as a routine part of the provision of care and do not rely
on the additional time and effort required to submit a spontaneous
report, (3) the sheer volume of data provides access to millions of
records, better reﬂecting actual medication-related usage than
demonstrated in a clinical trial, and (4) the current national focus
on EHR adoption [13] suggests the amount of available data will
only increase.
While observational data offer new opportunities, their use is
not without limitations. One particularly concerning challenge is
the ability to accurately identify health outcomes of interest
(HOIs). Administrative claims data, for example, are designed for
reimbursement, not clinical care documentation. When conducting
research with claims data, the lack of standards has resulted in out-
come deﬁnitions that rely on billing codes such as ICD-9-CM diag-
nosis codes or CPT procedure codes which may not accurately
reﬂect a patient’s clinical status or care delivery because of prob-
lems including sloppy coding, up-coding (e.g., assigning procedural
billing codes that commands higher reimbursement), or coding
that reﬂects clinical work-up to rule out a diagnosis [14]. As is evi-
dent from the literature, when these codes are used in research,
additional problems are introduced by the multitude of possible
combinations of codes that are included to deﬁne an HOI [15].
For example, one study might deﬁne acute myocardial infarction
as any ICD-9-CM diagnosis code beginning with 410, while another
study might include only 410.2 and 410.4, and a third might
require one of these eligible diagnosis codes plus a relevant
coronary artery bypass graft procedures (e.g., CPT codes 33510-
33536). Variability in which codes comprise deﬁnitions will impact
measurement.
If observational data are to be used reliably for active drug
safety surveillance, approaches to identifying HOIs must be im-
proved. To ﬁrst determine the variability across deﬁnitions, OMOP
funded two independent systematic literature reviews to detail
how studies of observational data deﬁned 10 example HOIs [15].
They concluded that large variability exists in the literature, and
no single deﬁnition of the HOIs they reviewed demonstrated clear
superiority. As a result, a library of competing, and in most cases
hierarchical, deﬁnitions for HOI measurement was developed
[16]. Further research is needed to identify best practices for mea-
suring HOIs in observational data.
We conducted methodological work to better understand how
HOI deﬁnitions in the OMOP library compare, and to explore
how these deﬁnitions might be reﬁned. To do this, we developed
a web-based dashboard to facilitate expert panel review of patient
cases with competing HOI deﬁnitions. To ensure patient conﬁden-
tiality, data needed to be under our control and securely accessed.
Additionally, panelists needed to review the data from disparate
locations with dynamic ﬁltering and sorting capabilities. We also
needed an efﬁcient mechanism to collect panelists’ assessments
and opinions for subsequent analysis, as well as the ability to con-
duct mediated disagreement resolution sessions that allowed
simultaneous review of panelists’ evaluations and patient data.
After considering our needs and available options, existing meth-
ods such as manual chart review and surveys were not deemed
suitable.
Expert panelists were presented observational data from a sam-
ple of patient cases identiﬁed by competing HOI deﬁnitions, and
were asked to provide opinions on whether they believed these pa-
tient data were consistent with having the HOI. Through dual,
independent panelist review and a mediated consensus process
for cases of disagreement, we were able to classify cases and create
a modeling dataset for studying HOI measurement.
In this paper, we present our review process and the Web dash-
board we created to efﬁciently present large volumes of data topanelists, capture panelists’ assessments, and resolve disagree-
ments. Speciﬁcally, we describe the development and implementa-
tion of: (1) a systematic case review and consensus-building
process; (2) a Web-based dashboard to present de-identiﬁed
claims and laboratory data; and (3) a process to collect case review
data in a manner enabling identiﬁcation and analysis of concepts of
interest that inﬂuenced panelists’ determination of presence/
absence of speciﬁc HOIs.2. Material and methods
2.1. Data sources and structure
The Truven MarketScan Lab Database (MSLR), licensed by
OMOP within their research lab on the Amazon EC2 cluster, pro-
vided the observational data source for this study. These data rep-
resent inpatient, outpatient, and pharmacy claims from
approximately 1.5 million privately insured patients from 2003
to 2007. The claims data are supplemented with laboratory results.
The MSLR data were transformed to the OMOP Common Data
Model (CDM), which is a data transformation that allows consis-
tent coding to be used across various types of observational data
sources [17]. Data transformed to the CDM are amenable to use
with publicly available OMOP tools for selecting cohorts (e.g., RICO
[16]) and producing standardized summaries (e.g., OSCAR [18] and
NATHAN [19]). Details on these tools can be found in the refer-
ences cited. The CDM provides a mechanism for combining multi-
ple occurrences of diagnosis codes and prescription drugs to deﬁne
eras of conditions or drug treatments which simpliﬁes the complex
data presentation. For our data presentation, we relied on the fol-
lowing data tables from the CDM: condition eras (e.g., combining
conditions with start and stop dates into eras), procedure occur-
rences, laboratory observations, visit occurrences, and drug eras
(e.g., continuous periods of drug ﬁlling with start and stop dates).2.2. Patient sample
Patients were sampled for competing HOI deﬁnitions using the
HOIs of acute liver injury (4 of 7 deﬁnitions), acute kidney injury (4
of 4 deﬁnitions), and myocardial infarction (3 of 4 deﬁnitions) [16].
For each HOI, we sampled cohorts of patients using a modiﬁed ver-
sion of OMOP’s Person-level Exploratory Data Review of Outcomes
(PEDRO). The PEDRO algorithm identiﬁed patients that met one or
more of our HOI deﬁnitions by assigning an identiﬁer (Concept ID)
to the patient record. The HOI deﬁnition-speciﬁc Concept ID was
attached to the patient’s record with the ﬁrst calendar date when
all of the conditions for group inclusion for an HOI deﬁnition were
met. This ﬁrst occurrence date when a patient became part of the
HOI cohort was recorded as the patient’s index date (time zero).
For purposes of strict data de-identiﬁcation, all elements of data
were anchored to this index date, with time preceding the index
date representing negative values and time following the index
date representing positive values.
Due to the hierarchical HOI deﬁnition relationships, the patient
cohort extraction process yielded patients meeting more than one
HOI deﬁnition option. For example, acute liver injury used a hier-
archical deﬁnition where the broadest deﬁnition only includes
diagnosis codes, a secondary deﬁnition includes both diagnosis
and procedure codes, and a third deﬁnition includes diagnosis
codes, procedures codes, and laboratory values. Patients meeting
the deﬁnition that includes diagnosis, procedures, and laboratory
values would also meet the previous two deﬁnitions. Because sam-
ple sizes were smaller for the most restrictive deﬁnitions and we
did not want to inadvertently exclude patients meeting the most
restrictive HOI deﬁnitions, we randomly sampled (without
Fig. 1. The initial landing page for panelists when reviewing an individual patient includes patient demographics, data ﬁlters, and observational data.
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then iteratively through deﬁnitions that were less restrictive. We
sampled a total of 612 patients: 208 for acute liver injury, 200
for acute kidney injury, and 204 for myocardial infarction. Power
calculations were not conducted, but rather the number of patients
was based on feasibility.
2.3. Expert panelists
Four panelists were recruited for each HOI. Using a modiﬁed
Delphi method, these four panelists were divided into two panels
to allow for independent, dual review of each patient case within
a single HOI. For example, panelists A and B independently re-
viewed half of the 200 cases for acute kidney injury while panelists
C and D independently reviewed the other 100 cases for this HOI.
Each panel consisted of a specialist for the HOI being studied
(i.e., a researcher with experience in observational studies of the
HOI with or without a clinical degree) and a generalist. The gener-
alists were required to have experience as a practicing physician
and applied experience working with or interpreting administra-
tive claims data.
2.4. Panelist dashboard
The panelist dashboard was designed to allow efﬁcient data
presentation so panelists could determine the patient’s HOI status,as well as capture factors that inﬂuenced panelists’ HOI determina-
tion. This also required several administrative functional elements:
(1) management of panelists, (2) assignment of patients to panel-
ists, (3) viewing panelists’ assessment data, (4) exporting panelists’
assessment data, and (5) management of the disagreement resolu-
tion process. Study investigators managed these administrative
functions. Additional functional elements of the dashboard in-
cluded technical (i.e., ‘‘backend’’) and user experience consider-
ations. Technical functional elements supported the management
of case review data that was presented to panelists. The user expe-
rience was largely dictated by the overall design of the dashboard,
including navigation, layout, and access.2.5. Case review
After reviewing patient data, panelists responded to a series of
questions: Question 1 Do you believe this case represents the
health outcome of interest? (yes/no); Question 2 To what extent
do you agree or disagree that this is a case of the health outcome
of interest? (1 = Strongly Disagree and 10 = Strongly Agree; Ques-
tion 3 To what extent do you rate the severity of the patient’s
health outcome of interest? (N/A, minor, moderate, severe, or
fatal); and Question 4 Which of the following contributed to your
decision?. Options included diagnoses, procedures, laboratory val-
ues, or drugs. Panelists indicated whether the presence, absence, or
number of each option inﬂuenced their classiﬁcation of the patient.
Fig. 2. A patient’s data has been narrowed to only include laboratory values of interest for the 2 years around the index date. The data have been sorted and highlighted.
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of events and their timing, and panelists were asked to check all
that apply. Visits were added to this grid for the myocardial infarc-
tion panel since whether patients received inpatient versus outpa-
tient care was identiﬁed by panelists as an important data element
in their review. Question 4 also included a text box that allowed
panelists to enter notes for the speciﬁc case. Kappa statistics as-
sessed inter-rater reliability for initial case review.
2.6. Disagreement resolution
Once initial case reviews were complete, answers from panelist
pairs reviewing the same patient were compared with respect to
their determination of the presence or absence of the HOI. We used
a consensus process to resolve disagreement on this question. Dis-
agreement resolution occurred during video conference meetings,
with a shared desktop image of the dashboard so patient data
could be reviewed as a group. Panelist pairs were simultaneously
presented their answers to questions 1 (case classiﬁcation), 2
(10-point likelihood scale), and 3 (severity scale), as well as any
comments entered on question 4. The resolution process was ledby 2 members of the research team. One member of the team con-
trolled the shared desktop, initially presenting the panelists’ eval-
uations. Panelists discussed the factors inﬂuencing their decisions,
with the researcher navigating through the patient’s data as dic-
tated by the panelists’ prompts. The other research team member
took notes from the discussion. After discussing each patient and
the available data, the panelists identiﬁed a consensus answer for
these three questions. The researcher recorded the consensus re-
sponses in the dashboard and moved to the next patient.
2.7. Data security and storage
All work with patient data was conducted on the Amazon Elas-
tic Compute Cloud (EC2), a web-based service that provides scal-
able computing capacity. For research staff or panelists to access
the de-identiﬁed patient data presentation portion of the dash-
board, a user ID and Web server password needed to be authenti-
cated. This information was passed directly from a Web server on
the Auburn University campus to the Amazon Web server. No
users of the system had both the user ID and the Amazon server
password. The Amazon EC2 was utilized for storage.
Fig. 3. This screen allowed panelists to see all highlighted rows (and corresponding values) for a patient prior to entering their assessment.
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All project work occurred between June, 2011, and June, 2012.
Web dashboard development took place during June through Sep-
tember, 2011, except for speciﬁc requests identiﬁed by panelists
during the review process. The Dashboard development was an
iterative process, whereby technical and clinical team members
regularly met and reviewed prototype functionality. This process
repeated until the live version of the dashboard was completed
and made available to panelists. During October, 2011, acute liver
injury patient samples were loaded in the dashboard and mock re-
views were conducted by research staff to test dashboard function-
ality. Also, prior to initiating their full case review, each panelist
pair reviewed 5 cases for understanding of the review process
and dashboard functionality. Questions originating from this initial
reviewwere addressed prior to full case review. The ﬁrst expert pa-
nel was launched in November, 2011.3.1. Presentation of patient data via the web dashboard
The presentation included a number of data attributes that
would facilitate the expert case review process. Available demo-
graphic information included age, sex, and eligible periods of
observation with respect to the HOI index date. Clinical data were
grouped as diagnoses, visits, procedures, laboratory values, and
drugs. Data were presented with descriptive labels rather than cor-
responding claims-based code values. Data were presented with a
‘‘Start’’ number, indicating their occurrence date in relation to the
patient’s qualiﬁcation for the HOI of interest, such that positive val-
ues indicate the event (i.e., diagnosis, visit, procedure, laboratory
value, and drug) occurred the corresponding number of days after
meeting HOI criteria, and negative values indicating the event oc-
curred prior to meeting HOI criteria.Fig. 1 depicts the ﬁrst screen that a panelist saw after selecting a
patient for review. The screen’s layout was modeled after eBay
Motors™, utilizing multiple ﬁlters and sorting options. eBay
Motors™ is a division of the online auction site, eBay, that focuses
speciﬁcally on the sale/purchase of automobile-related products. It
was selected as the template for the dashboard because it provides
efﬁcient ﬁltering and sorting functions that were deemed similar
to the needs for this project. The actual patient data, in table form,
subsume the majority of the window. Along the left side, starting
at the top, the panelists had access to patient demographic data
(age and gender), a ‘‘Days-to-index’’ slider, as well as ﬁlters. The
Days-to-index slider allowed panelists to narrow or widen the date
range from which data are displayed, anchored by the date of the
ﬁrst qualifying HOI-related observation. The ‘‘Eligible observation
period’’ was deﬁned as the range of days before and after the index
date for which we had any available observational data. Panelists
are also able to sort the data by date, as well as alphabetically,
by clicking the appropriate header in the patient data table.3.2. Priority concept ﬁlters
To make it as simple as possible for panelists to review data that
would be most relevant to their HOI classiﬁcation, we created ﬁl-
ters for priority concepts. Priority concept indicators were added
to all of the patient level data, which essentially allowed panelists
to view custom reports based on data most relevant to the HOI.
Available ﬁlters allowed panelists to ﬁlter data based on diagnoses,
visits, procedures, laboratory values, and drugs. The priority con-
cept ﬁlters were created through a multi-step process. First, we re-
viewed the literature and created a summary document for
diagnoses, procedures, labs, and treatments relevant to each HOI.
These documents were shared with the panelists and revised based
on their feedback. Second, we used these documents to create a
key word list for each HOI. These key words were then run against
Fig. 4. For each patient reviewed, panelists completed the HOI assessment depicted here. It included a variety of question types to allow panelists to provide as much
information as possible regarding how they made their case determination.
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ﬁeld of the key word were retained as a priority concept. For exam-
ple, if a descriptive text ﬁeld for a procedure code contained one or
more of the predetermined clinically meaningful text string items
or key words, the concept id for that procedure code would be
ﬂagged as a priority concept. For drugs, we ran these key words
against text strings for indications, contraindications, and off-label
uses listed in the OMOP Standard Vocabulary, which were derived
from the First DataBank NDDF Plus Source Vocabulary. For lab val-
ues, we ran the key word list against the Logical Observation Iden-
tiﬁers Names and Codes [20] (LOINC) database to identify the
LOINC terms that would constitute the laboratory priority
concepts.
Fig. 2 depicts several of the available sorting and ﬁltering fea-
tures. Speciﬁcally, this patient’s Days-to-index sliders have been
adjusted to include the year before and the year after their ﬁrst
qualifying HOI-related observation. The ﬁgure shows the patient’s
‘‘Lab Values of Interest’’, sorted by ‘‘Start’’ days-to-index. For lab
values, panelists were presented the reported value (when avail-
able), the reference range, and the upper limit of normal. For Diag-
noses and Procedures, panelists were able to further narrow the
data to the previously deﬁned concepts of interest. Visits couldbe narrowed to show any combination of ‘‘Inpatient Hospital’’,
‘‘Outpatient Hospital’’, and ‘‘Ofﬁce’’ visits. Medications could be
narrowed to ‘‘Indicated Drugs’’, ‘‘Drugs Used Off-Label’’, and ‘‘Con-
traindicated Drugs’’. Filters were applied by ﬁrst clicking the radio
button to the left of the primary ﬁlter (e.g., ‘‘All Diagnoses’’) and
then selecting the checkbox for the appropriate secondary ﬁlter
(e.g., ‘‘Diagnoses of Interest’’).3.3. Panelist clipboard for highlighting important data
Fig. 2 also depicts a highlighting feature within the dashboard,
which allowed panelists to mark data of interest by clicking on
the line of interest. A single click evokes a yellow highlight, signi-
fying that the panelist ﬁnds the observation generally interesting.
Clicking the same line of data a second time turns the row green,
signifying that the panelist identiﬁes the observation as a positive
indicator for the HOI. A third click turns the row red, signifying that
the panelist identiﬁes the observation as a negative indicator of the
HOI. A fourth click removes all highlighting. We incorporated this
feature for two reasons: (1) to assist panelists in their ﬁnal case
determination, and (2) to facilitate capture of those factors
Fig. 5. This view allowed project administrators to review completed case reviews.
B.I. Fox et al. / Journal of Biomedical Informatics 46 (2013) 795–804 801believed by the panelist to inﬂuence their assessment of the likeli-
hood that this is a ‘true’ case of the HOI.
Panelists then clicked ‘‘View selected rows’’ above the demo-
graphic data to view only the highlighted observations, as depicted
in Fig. 3. The colored highlights, as determined by the panelist,
were visible, along with the other data elements for each observa-
tion that had been highlighted. This intermediate step provided
panelists with a quick, focused view of the factors that they be-
lieved were important to case determination prior to entering their
assessment.
3.4. Panelist assessments
Panelists entered their assessment (described above) on the
screen shown in Fig. 4. Prior to arriving at this page, the panelists
have already viewed the patient data, ﬁltered, sorted, and high-
lighted as necessary, and are now ready to assess the likelihood
that this patient is a case of the HOI.
3.5. Functions to support project administration
Several functional abilities were incorporated into the dash-
board to support project administration, including: (1) manage-ment of panelists’ accounts, (2) assignment of panelists to
patients, (3) viewing panelists’ assessment data, (4) management
of the consensus building process, and (5) exporting panelists’
assessment data. Once panelists began case review, administrators
needed to be able to monitor panelists’ progress and identify any
potential problems with the case review process. Project adminis-
trators were able to view all highlighted rows by HOI. The dash-
board also identiﬁed individual patient cases in which panelist
pairs disagreed on the presence of the HOI. After consensus was
reached, the dashboard exported panelists’ assessment data to
Microsoft Excel for analysis.
Fig. 5 depicts the administrator view of patient cases that have
been assessed by at least one panelist. In the ﬁgure, the HOI is liver
injury (top left corner of the screen). In the blue row, ‘‘userID’’ is
the panelist who evaluated the case, and ‘‘Patient’’ signiﬁes the
particular patient case. When checked, the box below ‘‘ALI’’ (Acute
Liver Injury) indicates the panelists answered ‘‘yes’’ to Question 1
of the assessment (Fig. 4). ‘‘Certainty’’ corresponds with Question
2. ‘‘Severity’’ corresponds with Question 3. Columns ‘‘Q4A’’ thru
‘‘Q4F’’ correspond, in order, to the various parts of Question 4.
For example, ‘‘Q4A’’ corresponds to ‘‘No occurrences BEFORE index
date’’. The four-lettered combinations of Ns and Ys under ‘‘Q4A’’ -
‘‘Q4F’’ correspond, in order, with panelists’ responses to the ‘‘Diag-
Fig. 6. Through the use of the consensus screen, panelists and research personnel were able to resolve disagreements in HOI determination.
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question 4. Here, ‘‘N’’ corresponds to an unchecked box, and ‘‘Y’’
corresponds to a checked box. ‘‘Time’’ signiﬁes when the panelist
completed the assessment, and ‘‘Description’’ corresponds to com-
ments entered in the Question 4 textbox.
Fig. 6 depicts the consensus building screen. ‘‘liverGroupB’’ is
the consensus user account. Panelists’ independent case determi-
nations (Fig. 4) are depicted in the ﬁrst two rows below the pa-
tient’s data. The consensus panel moderator entered ﬁnal
determinations in the third row, and this became the ﬁnal data
for disagreement cases. The two acute liver injury panels had 16
and 18 cases requiring consensus discussion. The two acute kidney
injury panels had 52 and 26 consensus cases, and the two myocar-
dial infarction panels had 20 and 21 cases. Consensus discussions
for liver and MI lasted approximately 1 h each; acute kidney injury
discussions lasted approximately 2 h and 1 h 30 min, respectively.4. Discussion
The primary focus of this methods research was to design, de-
velop, and implement a systematic case review and consensus-
building process for expert panelists’ review of de-identiﬁed obser-
vational data using a Web-based dashboard. Existing OMOP tools
such as RICO and PEDRO allowed for efﬁcient identiﬁcation of pa-tients and the CDM structure could be intuitively presented to pan-
elists. The expert panel review could be conducted remotely from
anywhere with high speed internet connectivity allowing connec-
tion to the Amazon cloud. The review process provided modeling
data sets that can be used to create better case deﬁnition methods.
While previous research has explored numerous methods to iden-
tify and validate medication-related health outcomes of interest in
a variety of data sources, we are aware of no studies utilizing a dis-
tributed research network of expert panelists to conduct Web-
based case reviews from a distance with a shared dashboard for
case evaluation and disagreement resolution [12,21–27].
Panelists’ anecdotal comments indicated that the dashboard
was efﬁcient and easy to use, including the initial learning curve.
This was supported by receipt of few questions beyond basic nav-
igation functions after panelists’ initial review of 5 cases to become
familiar with the process and only one request for assistance via
the built-in Help feature during the entire course of the project.
Panelists indicated that the time required to complete a case re-
view was reasonable once becoming familiar with the dashboard,
suggesting a usual review time of 1–5 min. Panelists’ comments
to the research team highlighted a primary challenge of working
with observational data: case determination was based solely on
the available data. During consensus discussions, panelists often
suggested more data would help guide their ﬁnal decision. For
example, the data source sometimes lacked actual laboratory re-
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data source, not of our review process or dashboard.
The method by which we implemented the severity question
on the panelist’s assessment screen is a limitation in our ap-
proach. We added this question based on the recommendation
of a reviewer after their initial review of 5 patients to become
familiar with the dashboard and process. Although all panelists
were presented this question for all patients, we did not explicitly
review criteria for each level of severity with each panelist. As a
result, panelists’ perceptions of severity may not be consistent.
However, discussions during the disagreement resolution process
suggested that panelists’ internal criteria for levels of severity
were similar.
We implemented a robust, Web-based dashboard that facili-
tated case review by panelists from disparate locations. Panelist
and patient case management within the dashboard was a core
functionality that performed consistently. The dashboard per-
formed reliably for data presentation, panelist assessment, and
assessment data capture functions. Discussions with panelists sug-
gested that panelists’ ﬁrst step in narrowing the available data in-
cluded sorting the labs of interest alphabetically, and then
examining the lab results in relation to the index date. While the
speciﬁc HOI sometimes inﬂuenced whether labs or diagnoses were
examined ﬁrst, we observed this behavior consistently from panel-
ists. These observations underscore the importance of ﬁltering and
sorting to enable panelists’ review, validating the multi-step pro-
cess of creating priority concepts. For some HOIs, we found that
case review could be expedited by modifying the default range
for the days-to-index slider to reﬂect clinical practice. For example,
the default range was changed to the 60 days before and 60 days
after the index date for myocardial infarction to assist panelists’
assessment of any observations that could inform their case
determination.
The highlight feature allowed panelists to create a color-coded
clipboard of important data for making their assessments. This
helped with efﬁciency in their review process. The highlighted data
also provided our research team with indicators of what panelists
were focusing on. Our future research will explore and model these
highlighted data as one means of trying to reﬁne case deﬁnitions
for HOIs.
The consensus-building process worked well. Although we
anticipated a consensus-building process would be necessary, we
did not initially build this function into the dashboard. Once con-
structed and tested, the function supported a total of 6 consensus
discussions. Panelists valued seeing their paired reviewer’s assess-
ment and comments. During consensus discussions, it was not
uncommon for one panelist to identify an important observation
that the other overlooked. It was also common for panelist pairs
to agree that a speciﬁc laboratory test, diagnosis, or other observa-
tion would substantially impact their ability to determine the sta-
tus of the HOI.
We believe that our methods research produced a reliable, scal-
able systematic case review and consensus-building process for ex-
pert panelists’ review of de-identiﬁed observational data using a
Web-based dashboard. We believe the ability to perform reviews
anywhere (with Internet access) at any time is an important fea-
ture of our methods. We reﬁned our processes for data manage-
ment and panelist training, case-review, and consensus-building
through each subsequent HOI. Our work is limited by the total
number of HOIs and panelists who participated in the project. Fu-
ture work should explore other HOIs and include larger numbers of
panelists to identify additional modiﬁcations that are necessary in
the dashboard and review process. The process we describe pro-
vides tools to efﬁciently collate, ﬁlter, and sort electronic data.
However, additional work is needed to directly compare our meth-
ods to existing methods.5. Conclusions
An expert panel review of patient data was effectively facili-
tated by our Web-based dashboard. Panelists were able to review
patient cases and classify whether identiﬁed cases were true or
false positives. Data generated from this process can be used to re-
ﬁne case identiﬁcation methods, which ultimately will improve the
ability to identify drug-related adverse events in observational
data. This approach may be useful in other areas of research and
quality assurance that require detailed record review. Its utility
may improve substantially in those data sources populated with
more extensive standardized information.Funding
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